Literature DB >> 10208482

Expression of plasminogen activator inhibitor-1 in human adipose tissue: a role for TNF-alpha?

M Cigolini1, M Tonoli, L Borgato, L Frigotto, F Manzato, S Zeminian, C Cardinale, M Camin, E Chiaramonte, G De Sandre, C Lunardi.   

Abstract

Elevated plasminogen activator inhibitor-1 (PAI-1) plasma levels, responsible for reduced fibrinolysis, are associated with animal and human obesity and with increased cardiovascular disease. The expression of PAI-1 has been found recently in animal and human adipose tissue. Factors and mechanisms regulating such an expression remain to be elucidated. In omental and/or subcutaneous biopsies from obese non-diabetic patients, incubated in Medium 199, we have confirmed that human adipose tissue expresses PAI-1 protein and mRNA; furthermore we have demonstrated that such an expression is clearly evident also in collagenase isolated human adipocytes and that it is stimulated by incubation itself and enhanced by exogenous human tumor necrosis factor-alpha (h-TNF-alpha). Since human adipose tissue produces TNF-alpha, to further characterize the relationship of PAI-1 to TNF-alpha, human fat biopsies were also incubated with Pentoxifylline (PTX) or Genistein, both known to inhibit endogenous TNF-alpha through different mechanisms. PTX caused a dose-dependent decrease of basal PAI-1 protein release, reaching 80% maximal inhibitory effect at 10(-3)M, the same inhibitory effect caused by Genistein at 100 microg/ml. This was associated to a marked inhibition of PAI-1 mRNA and of endogenous TNF-alpha production. Furthermore, when human fat biopsies were incubated in the presence of polyclonal rabbit neutralizing anti-human TNF-alpha antibody (at a concentration able to inhibit 100 UI/ml human TNF-alpha activity), a modest but significant decrease of the incubation induced expression of PAI-1 mRNA was observed (19.8+/-19.0% decrease, P = 0.04, n = 7). In conclusion, the results of this study demonstrate that PAI-I expression is present in human isolated adipocytes and that it is enhanced in human adipose tissue in vitro by exogenous TNF-alpha. Furthermore our data support the possibility of a main role of endogenous TNF-alpha on human adipose tissue PAI-1 expression. This cytokine, produced by human adipose tissue and causing insulin resistance, may be a link in the clinical relationship between insulin-resistance syndrome and increased PAI-1 plasma levels.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10208482     DOI: 10.1016/s0021-9150(98)00281-0

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  21 in total

1.  Acute and prolonged effects of TNF-alpha on the expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture.

Authors:  Bohan Wang; Paul Trayhurn
Journal:  Pflugers Arch       Date:  2006-04-04       Impact factor: 3.657

2.  Metabolic effects of obesity: A review.

Authors:  Parul Singla; Animesh Bardoloi; Anuj A Parkash
Journal:  World J Diabetes       Date:  2010-07-15

3.  Thrombin promotes diet-induced obesity through fibrin-driven inflammation.

Authors:  Anna K Kopec; Sara R Abrahams; Sherry Thornton; Joseph S Palumbo; Eric S Mullins; Senad Divanovic; Hartmut Weiler; A Phillip Owens; Nigel Mackman; Ashley Goss; Joanne van Ryn; James P Luyendyk; Matthew J Flick
Journal:  J Clin Invest       Date:  2017-07-24       Impact factor: 14.808

Review 4.  Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions.

Authors:  Matteo Cesari; Marco Pahor; Raffaele Antonelli Incalzi
Journal:  Cardiovasc Ther       Date:  2010-07-07       Impact factor: 3.023

5.  Tumor necrosis factor alpha is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1.

Authors:  F Samad; K T Uysal; S M Wiesbrock; M Pandey; G S Hotamisligil; D J Loskutoff
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

Review 6.  Vascular biology of metabolic syndrome.

Authors:  Daynene Vykoukal; Mark G Davies
Journal:  J Vasc Surg       Date:  2011-03-24       Impact factor: 4.268

Review 7.  Adipocytokines and the metabolic complications of obesity.

Authors:  Neda Rasouli; Philip A Kern
Journal:  J Clin Endocrinol Metab       Date:  2008-11       Impact factor: 5.958

8.  Pre- and post-translational negative effect of beta-adrenoceptor agonists on adiponectin secretion: in vitro and in vivo studies.

Authors:  Marie-Laure Delporte; Tohru Funahashi; Masahiko Takahashi; Yuji Matsuzawa; Sonia M Brichard
Journal:  Biochem J       Date:  2002-11-01       Impact factor: 3.857

9.  Thrombospondin-1 is an adipokine associated with obesity, adipose inflammation, and insulin resistance.

Authors:  Vijayalakshmi Varma; Aiwei Yao-Borengasser; Angela M Bodles; Neda Rasouli; Bounleut Phanavanh; Greg T Nolen; Emily M Kern; Radhakrishnan Nagarajan; Horace J Spencer; Mi-Jeong Lee; Susan K Fried; Robert E McGehee; Charlotte A Peterson; Philip A Kern
Journal:  Diabetes       Date:  2007-12-05       Impact factor: 9.461

10.  Beneficial metabolic effects of CB1R anti-sense oligonucleotide treatment in diet-induced obese AKR/J mice.

Authors:  Yuting Tang; George Ho; Yaxin Li; Meghan A Hall; Robert L Hills; Shawn C Black; Yin Liang; Keith T Demarest
Journal:  PLoS One       Date:  2012-08-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.